Request Processed

Your registration request has been processed. We will contact you soon.

Register

PrevisionPolicy logo
  • Login
  • Register
  • About
  • Contact Us
1 2 3 4 5 6 Next › Last »

Prevision Policy Clips | Part D “Smooth” Co-Pay Guidance Will Be Issued In Two Parts, CMS Says

August 22, 2023

FDA Informed Consent Guidance Sticks To Themes Of Establishing Safeguards In Complex Research Populations But Gives IRBs Flexibility When “New Information” Arises

August 21, 2023

Prevision Policy Clips | Amgen Lumakras AA Conversion Application Will Provide ODAC Case Study For “Successful” PFS Trial With Adverse Survival

August 21, 2023

Biosimilar Supplement Applications: FDA Offers Details On New Review Categories Under BsUFA III

August 18, 2023

Prevision Policy Clips | Hydroxychloroquine, Ephedrine Fail To Make FDA 503B Bulk Drug List For Compounding By Outsourcing Facilities

August 18, 2023

Prevision Policy Clips | Labeling For Biosimilar And Interchangeable Products Draft Guidance Under Review At OMB

August 17, 2023

Prevision Policy Clips | AZ Warning Letter For Breztri Aerosphere Is First Issued By FDA Office of Prescription Drug Promotion In 2023

August 16, 2023

Prevision Policy Clips | US WorldMeds Eflornithine Neuroblastoma Relapse Prevention NDA Will Be Reviewed By ODAC On October 4

August 15, 2023

Prevision Policy Clips | CDER Net Hiring Far Outpacing CBER With 186 New Hires Compared To Only Three Net Gains

August 14, 2023

Postmarket Data Collection Guidance For Underrepresented Groups Provides Broad FDA Advice On Approaches; Real-World Data Among Options

August 11, 2023

Prevision Policy Clips | Value-Based Purchasing Agreements In ALS: “There’s No Leverage”

August 11, 2023

Prevision Policy Clips | Postmarket Data Collection Guidance On Underrepresented Populations Features “Mechanisms” By Which FDA Can Request Or Require Information

August 10, 2023

Sickle Cell Gene Therapies Continue ICER Positive Gene Therapy Reviews; Past Inequities Create Favorable Context For Price/Coverage

August 9, 2023

Prevision Policy Clips | Postapproval Pregnancy Safety Studies: FDA/Duke Margolis Workshop Sept. 18-19

August 9, 2023

QTc Labeling Draft Guidance For Non-Antiarrhythmic Drugs: “Reasonable Evidence” Of Causal Cardiac Events Should Result In Boxed Warning, FDA Says

August 8, 2023

Prevision Policy Clips | FDA Schedules Listening Session On Product Recalls For Sept 29

August 8, 2023

Prevision Policy Clips | Sage/Biogen Zurzuvae Split Decision By FDA Approves Post-Partum Depression

August 7, 2023

Prevision Policy Clips | AZ/Sanofi Beyfortus Enthusiastically Endorsed By ACIP, Despite Concern About Price

August 4, 2023

Office Of Therapeutic Products Director Verdun Is A CBER Veteran; Internal Candidate Chosen For High-Profile Post Overseeing Gene/Cell Therapy Reviews

August 3, 2023

Prevision Policy Clips | CBER OTP Head: Blood Office Director Nicole Verdun

August 3, 2023

Essential Medicine “Buffer Stock” Incentive For Hospitals Floated By CMS As Potential Tool To Prevent Shortages

August 3, 2023

FDA Advisory Committee Revamp Will Focus On Streamlined Logistics For Members, Cross-Cutting Regulatory Topics And Hybrid Meetings

August 2, 2023

NTAP Class Of 2024 Includes 11 New Drugs; CMS Changes Timelines For Future Applicants For Hospital Add-On Payments

August 2, 2023

Prevision Policy Clips | CMS Grants New Technology Add-on Payments For 11 New Drugs, Changes Timelines For Future NTAP Requests

August 2, 2023

Advisory Committee Tracker: Alnylam Onpattro sNDA, BrainStorm Filed-Over-Protest BLA Offer Contrasting Rare Disease Reviews For September

August 1, 2023
1 2 3 4 5 6 Next › Last »

Patient-Focused
Drug Development
Database

Access database reports on PFDD meetings.

Log In
LEARN MORE
PrevisionPolicy logo sailboat

What is Prevision Policy?

Prevision Policy provides breaking analysis for biopharma on drug regulation, policy and market access. Our continuous information service gives decision makers actionable insight when they need it most on FDA, CMS, Congress, and how developments in policy impact commercial success.

Prevision Policy was started with the belief that information must be trustworthy, interactive, fast as it is deep, and deliver the bottom line. Strategy is developed in real-time and the biopharma business landscape can change quickly and without warning. Our service has been developed to address those challenges and turn them into opportunities.

To request more information about a company license to the Prevision Policy continuous information service or to get further details about the services we offer, please click here.

Biopharma Congress

Copyright © 2023 Prevision Policy. All Rights Reserved. Privacy Policy